49851-55-0

Basic information

• Product Name: 2-Bromophenacyl bromide, 90%
• Synonyms: 2-Bromo-2'-bromoacetophenone;2-Bromo-1-(2-bromophenyl)ethan-1-one;2-Bromo-1-(2-bromophenyl)ethanone;2-Bromophenacyl bromide;2-Bromo-1-(2-bromophenyl)ethan-1-one, 2,2'-Dibromoacetophenone;2-Bromophenacylbromide90%;2-Bromophenacylbromide97%
• CAS NO: 49851-55-0
• Molecular Formula: C₈H₆Br₂O
• Molecular Weight: 277.94
• Mol File: 49851-55-0.mol
• Article Data: 54

Chemical Properties

• Boiling Point: 90-92°C/0.02mm
• Flash Point: 108.1 °C
• Appearance: /
• Density: 1.848 g/cm³
• Vapor Pressure: 0.00116mmHg at 25°C
• Refractive Index: 1.6100-1.6140
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Sensitive: Lachrymatory
• CAS DataBase Reference: 2-Bromophenacyl bromide, 90%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromophenacyl bromide, 90%(49851-55-0)
• EPA Substance Registry System: 2-Bromophenacyl bromide, 90%(49851-55-0)

Safety Data

• Hazard Codes: C
• RIDADR: 3261
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 49851-55-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromophenacyl bromide, 90% is used as a synthetic intermediate for the preparation of various pharmaceutical compounds. Its reactivity allows for the formation of new chemical entities with potential therapeutic applications.
Used in Chemical Synthesis:
2-Bromophenacyl bromide, 90% is used as a reagent in the synthesis of various organic compounds, including those with potential applications in the fields of materials science, agrochemicals, and specialty chemicals.
Used in Research and Development:
2-Bromophenacyl bromide, 90% is utilized in research laboratories for the development of new chemical reactions and the exploration of novel synthetic pathways. Its unique reactivity makes it a valuable tool for chemists working on the design and synthesis of new molecules.
Used in the Preparation of 4-Phenylthiazol-2(3H)-one Derivatives:
2-Bromophenacyl bromide, 90% is used as a key intermediate in the preparation of 4-phenylthiazol-2(3H)-one derivatives, which are known for their anticonvulsant properties. This application highlights the compound's utility in the development of new therapeutic agents for the treatment of epilepsy and other seizure disorders.

InChI:InChI=1/C8H6Br2O/c9-5-8(11)6-3-1-2-4-7(6)10/h1-4H,5H2

Upstream product

• 2142-69-0 2-bromophenyl methyl ketone 
• 46004-44-8 2-bromo-ω-diazoacetophenone 
• 7154-66-7 2-bromobenzoic acid chloride 
• 2042-37-7 o-cyanobromobenzene 
• 4001-73-4 2-Bromobenzamide 
• 88-65-3 2-bromobenzoic-acid 
• 1973-22-4 1-bromo-2-ethylbenzene 
• 2039-88-5 2-bromostyrene 
• 401514-46-3 1-(bromoethynyl)-2-bromobenzene 
• 6630-33-7 ortho-bromobenzaldehyde 

Downstream Products

• 49851-47-0 2-(2-bromo-phenyl)-6-chloro-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-2-ol 
• 49851-50-5 2-(2-bromo-phenyl)-6-chloro-3H-pyrido[2,3-b][1,4]thiazine 
• 79965-72-3 4-(2-bromophenyl)-2-methyloxazole 
• 137092-38-7 Dithiopivalinsaeure-2-<(2-bromphenyl)-2-oxoethyl>ester 
• 24251-10-3 o-Brom-phenacyl-phenylsulfid 
• 171734-91-1 1-<2-(2-bromophenyl)-2-oxoethyl>-1H-indole-3-carboxaldehyde 
• 320371-89-9 1-(2-bromo-phenyl)-2-(4-methoxy-phenoxy)-ethanone 
• 363186-30-5 1-(2-bromophenyl)-2-(2-naphthylthio)ethanone 
• 126961-71-5 1-(2-Bromo-phenyl)-2-[1,2,4]triazol-1-yl-ethanone 
• 126961-75-9 1-(2-Bromo-phenyl)-2-[1,2,4]triazol-1-yl-ethane-1,2-dione 2-oxime 
• 115769-03-4 2-(2-bromophenyl)imidazo[1,2-α]pyridine 
• 1207477-00-6 C₃₂H₂₄BrN₃O₃ 
• 1215858-73-3 C₈H₇Br₂NO 
• 1276043-59-4 C₁₅H₁₄Br₂N₂O₂S 

Relevant articles and documents

Synthesis and anti-methicillin-resistant Staphylococcus aureus activity of 5,7-dibromo-2-benzoylbenzofurans alone and in combination with antibiotics

A series of 5,7-dibromo-2-benzoylbenzofurans were synthesized by the Rap–Stoermer condensation of 5,7-dibromosalicylaldehyde with diverse phenacyl bromides and evaluated for in-vitro antibacterial activities against methicillin-sensitive Staphylococcus aureus (MSSA) ATCC 29213, methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300, and MRSA ATCC 33591 by agar dilution method. The synergistic effects were determined by using the agar dilution checkerboard assay. The derivatives bearing carboxylic acid functional groups exhibited reasonable activity against MRSA strains with the best MIC = 32 μg/mL (9b, 9d). Moreover, the additive or synergistic interactions against MRSA strains was observed in six combinations (1b + cefuroxime/gentamicin, 1c + ciprofloxacin/gentamicin, 9b + gentamicin, and 9c + ciprofloxacin) with the fractional inhibitory concentration index (FICI) values in the range of 0.375–1.0. Significantly, the MICs of these antibiotics were reduced 2–4-fold. The results of the MTT assay illustrated the low mammalian cell cytotoxicity of these potent compounds.

Ru-Tethered (R,R)-TsDPEN with DMAB as an efficient catalytic system for high enantioselective one-pot synthesis of chiral β-aminolviaasymmetric transfer hydrogenation

This work reflects Ru-tethered-TsDPEN as an active chiral catalyst for one pot selective synthesis of optically active α-substituted alcohols and its derivatives from α-bromo ketones in the presence of dimethylamine borane (DMAB) as the hydrogen source. Various Ru-chiral catalysts have been screened and the methodology proceededviaa (R,R) Ru-tethered TsDPEN catalyst through asymmetric transfer hydrogenation (ATH) of the in-situ formed ketones to the corresponding chiral β-aminol product. Thus, the Ru-tethered TsDPEN-DMAB catalytic system works efficiently with higher yield and high enantiomeric excess over others for the ATH process. Based on a study ofortho,metaandparasubstituted α-bromo acetophenone derivatives, effective enantioselectivity has been observed fororthosubstituted β-aminol. The mechanism has been optimized depending on product analysis with the help of its kinetic AT-IR study. This work also focusses on the synthesis of various β-amino alcohol derivatives where the effect of an EWG and EDG on enantio-selectivity has been studied.

SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Selective Debromination of α,α,α-Tribromomethylketones with HBr–H2O Reductive Catalytic System

A debromination of α,α,α-tribromomethylketones is developed for chemoselective synthesis of α-mono- and α,α-dibromomethylketones with high selectivity under H2O–HBr reductive conditions. This method offers an efficient and direct way to synthesize α-mono or α,α-dibromomethylketone compounds in high to excellent yields through the process of HBr self-circulation in water.

Synthesis of 5-Aryl-5H-pyrido[2',1':2,3]imidazo[4,5-b]indoles by Domino Pd- and Cu-Catalyzed C-N Coupling Reactions

A series of 5-aryl-5H-pyrido[2',1':2,3]imidazo[4,5- b ]indoles was successfully prepared in good yields by a practical four-step strategy. In this procedure, the key step was demonstrated to be the domino Pd-and Cu-catalyzed C-N coupling reactions of 3-br

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

Antibacterial synergist, preparation method and uses thereof

The present invention relates to an antibacterial synergist, a preparation method and uses thereof, and specifically discloses a compound represented by a formula (I) and having antibacterial synergyactivity, or an optical isomer, a cis-trans isomer or a pharmaceutically acceptable salt thereof, and a preparation method thereof. The present invention further discloses a medical composition containing the compound, and uses thereof. According to the present invention, the compound can effectively enhance the antibacterial activity of polymyxin B against Acinetobacter baumannii and Klebsiella pneumoniae, and can be used for the antibacterial treatment of pathogenic bacteria insensitive to polymyxin or having low bacterial inhibition activity. The formula (I) is defined in the specification.

CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

A condensed cyclic compound and an organic light-emitting device including the same are provided. The organic light-emitting device includes a first electrode, a second electrode, and an organic layer disposed between the first electrode and the second el

N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model

Free fatty acid-2 (FFA2) receptor is a G-protein coupled receptor of interest in the development of therapeutics in metabolic and inflammatory disease areas. The discovery and optimization of an N-thiazolylamide carboxylic acid FFA2 agonist scaffold is described. Dual key objectives were to i) evaluate the potential of this scaffold for lead optimization in particular with respect to safety de-risking physicochemical properties, i.e. lipophilicity and aromatic content, and ii) to demonstrate the utility of selected lead analogues from this scaffold in a pertinent in vivo model such as oral glucose tolerance test (OGTT). As such, a concomitant improvement in bioactivity together with lipophilic ligand efficiency (LLE) and fraction sp3 content (Fsp3) parameters guided these efforts. Compound 10 was advanced into studies in mice on the basis of its optimized profile vs initial lead 1 (ΔLLE = 0.3, ΔFsp3 = 0.24). Although active in OGTT, 10 also displayed similar activity in the FFA2-knockout mice. Given this off-target OGTT effect, we discontinued development of this FFA2 agonist scaffold.

Efficient sulfonylation of ketones with sodium sulfinates for the synthesis of β-keto sulfones

The oxidative sulfonylation of ketones with sodium sulfinates as the sulfone source and DMSO as the oxidant is reported. A series of β-keto sulfones were obtained in good to excellent yields. The advantages of this efficient protocol include the low cost of DMSO and HBr, and a broad scope.